Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma
Top Cited Papers
- 1 May 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (13) , 1651-1657
- https://doi.org/10.1200/jco.2006.06.6514
Abstract
Purpose This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging...Keywords
This publication has 22 references indexed in Scilit:
- Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumoursEuropean Journal Of Cancer, 2003
- αvβ3 and αvβ5 Integrin Expression in Glioma PeripheryNeurosurgery, 2001
- αvβ3 and αvβ5 Integrin Expression in Glioma PeripheryNeurosurgery, 2001
- Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an αv Integrin AntagonistNeurosurgery, 2001
- Platelet‐derived growth factor in human gliomaGlia, 1995
- Integrins: A family of cell surface receptorsCell, 1987
- Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial originNature, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958